Silo Pharma (OTCQB: SILO) earlier this year extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). “Silo’s partnership with UMB focuses on peptides used for investigating and treating the arthritogenic process or joint disease. Current treatment for arthritis has side effects that include nausea, vomiting, diarrhea, tinnitus, hair loss, seizures, fever, congestion, unusual lumps or masses, and more. OTC arthritis therapeutics, such as common NSAIDs, can produce stomach ulcers, dizziness and indigestion and can have unpredictable results with other medications. Silo’s novel inventions could greatly limit or eliminate these side effects. Silo and UMB are also investigating central nervous system (‘CNS’) homing peptides to deliver targeted payloads of psilocybin for treating multiple sclerosis (‘MS’) and other neuroinflammatory diseases. These peptides are designed to address numerous challenges…” a recent article reads. Silo CEO Eric Weisblum is quoted saying, “The ability to deliver conventional and novel therapeutic compounds directly to targeted areas of the body with homing-peptide technology could be significant by increasing the efficacy of the treatment while reducing the amount of medicine needed…”
To view the full article, visit https://ibn.fm/5P9Qm
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
